Identification of clinical risk factors of atrial fibrillation in congestive heart failure

Targoński, Ryszard; Sadowski, J; Romaszko, Jerzy; Cichowski, Leszek

doi:10.5603/cj.2013.0094

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, preoperative in ammatory markers, such as white blood cell count, are widely recognized as predictive factors for POAF [15][16] . However, related research on the impact of preoperative in ammatory indices on the development of POAF following lung cancer surgery is rare.…”

Section: Discussionmentioning

confidence: 99%

Impact of Preoperative Inflammatory Indices and Postoperative Pneumonia on Postoperative Atrial Fibrillation in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Ruan,

Han,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: This study aimed to evaluate the impact of preoperative inflammatory indices and postoperative pneumonia (POP) on postoperative atrial fibrillation (POAF) in non–small cell lung cancer (NSCLC) patients. Methods: All consecutive patients who underwent pulmonary resection at our hospital (January 2016-October 2019) were enrolled. Preoperative inflammatory indices, demographic data, surgical details, and postoperative conditions were analyzed. Univariate and multivariate analyses of risk factors associated with POAF were also conducted. Results: Among the 382 patients included in the study, 32 (8.38%) developed POAF. Approximately 31 patients (96.9%) developed atrial fibrillation within three days after surgery. The POAF group had a significantly greater mean age (68 years) than did the non-POAF group (62 years) (P=0.002). Additionally, compared with non-POAF patients, POAF patients exhibited an increased number of mediastinal lymph nodes (P<0.001) and mediastinal lymph node stations (P<0.001). The POAF group also had a greater intraoperative blood volume (P=0.006), longer surgical duration (P=0.022), greater incidence of POP (P=0.09), and greater drainage volume (P=0.003). TNM stage (P<0.001) and type of lung resection (P=0.049) were also associated with POAF. Compared to those in the non-POAF group, the POAF group had longer postoperative hospital stays (10.54 days vs. 9 days; P=0.001) and longer drainage times (7 days vs. 5 days; P=0.004). Multivariate analysis revealed age, POP grade, and TNM stage as independent predictors of POAF in NSCLC patients. Conclusion: Preoperative inflammatory indices were not significantly associated with POAF, but age, POP, and TNM stage were identified as independent predictors. Early-stage NSCLC patients may have a greater susceptibility to POAF than early-stage patients, although further validation is needed. Additionally, POAF was linked to a longer postoperative hospital stay.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Preoperative Inflammatory Indices and Postoperative Pneumonia on Postoperative Atrial Fibrillation in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Ruan,

Han,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The obtained results cannot be unequivocally compared with risk factors, which were defined in the literature as predisposing to the occurrence of AF, because they were evaluated for the general population including patients with heart failure and preserved ejection fraction. We still do not know if the same risk factors identified in the general population can be applied to patients with heart failure [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of Atrial Fibrillation in Heart Failure Patients With Implantable Cardioverter Defibrillator or Cardiac Resynchronisation Therapy.

et al. 2021

View full text Add to dashboard Cite

IntroductionImplantable cardioverter defibrillators register various types of arrhythmias. Thus they can be exploited to better identify patients with atrial fibrillation episodes and increase the proportion of patients who may benefit from implementation of pharmacological prophylaxis of thromboembolic events, most of which it turns out are asymptomatic.Material and methodsAssessment of the frequency, symptoms and predisposing factors for the occurrence of atrial fibrillation episodes in patients with implanted ICD (implantable cardioverter defibrillator) and CRT-D (cardiac resynchronisation therapy with defibrillator) based on the analysis of intracardiac electrocardiograms (IEGM) records. The study included 174 consecutive outpatient cases with heart failure, sinus rhythm and Implanted Cardioverter Defibrillator and Cardiac Resynchronisation Therapy with Defibrillator. Control visits with analysis of IEGM records occurred every three months. During mean follow-up of 20 months, 901 visits were carried out. 147 patients had at least one year of follow-up.ResultsAtrial fibrillation episodes in the study group occurred in 54 (31.0%) of patients and 71.4% were asymptomatic. Predisposing factors were: history of paroxysmal atrial fibrillation (37.0% vs 13.3%, p ˂ 0.001), atrioventricular conduction abnormalities (42.6% vs. 20.0%, p = 0.002), intraventricular conduction abnormalities (59.3% vs 40.8%, p = 0.02) and more severe mitral regurgitation (7.4% vs 0.8%, p = 0.04). Chronic renal disease was a risk factor for death in the study group. No stroke occurred during the study.ConclusionsEpisodes of paroxysmal AF in patients with systolic heart failure and implanted cardioverter-defibrillator systems are quite common. The majority of the episodes recorded in the study were asymptomatic.

show abstract

“…[14][15][16]. The proportion of those with HF who also have AF increases with New York Heart Association (NYHA) class, from 5% in NYHA I to 49% in NYHA IV [17].…”

Section: Atrial Fibrillation and Heart Failurementioning

confidence: 99%

Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant

Brown

Boos

2017

International Journal of Cardiology

View full text Add to dashboard Cite

Atrial fibrillation (AF) and heart failure (HF) frequently coexist. AF is identified in approximately one third of patients with HF and is linked to increased morbidity and mortality than from either condition alone. AF is relatively more common in HF with preserved ejection fraction (HFpEF) than with reduced ejection fraction (HFrEF).Nevertheless, the risk of stroke and systemic embolism (SSE) is significantly increased with both HF types and the absolute risk is heavily influenced by the presence and severity of associated additional stroke risk factors. The European Society of Cardiology has very recently introduced a third HF subtype entitled HF with mid-range ejection fraction (HFmrEF). At present oral anticoagulation is recommended for all patients with AF and HF, independent of HF type. In addition to warfarin there are currently four non-vitamin K oral anticoagulants (NOACs, previously called novel oral anticoagulants) that have been approved for the prevention of SSE. They consist of one direct thrombin inhibitor, dabigatran and three factor Xa inhibitors: rivaroxaban, apixaban and, most recently, edoxaban. In this review article we present an overview of the evidence to support the use of NOACs for the prevention of SSE in patients with AF and HF and review the influence of HF subtype and co-morbidities on the potential choice of oral anticoagulant.

show abstract

Identification of clinical risk factors of atrial fibrillation in congestive heart failure

Abstract: (Cardiol J 2013; 20, 4: 364-369)

Cited by 3 publications

References 20 publications

Impact of Preoperative Inflammatory Indices and Postoperative Pneumonia on Postoperative Atrial Fibrillation in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Impact of Preoperative Inflammatory Indices and Postoperative Pneumonia on Postoperative Atrial Fibrillation in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Diagnosis of Atrial Fibrillation in Heart Failure Patients With Implantable Cardioverter Defibrillator or Cardiac Resynchronisation Therapy.

Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant

Contact Info

Product

Resources

About